tiprankstipranks
Trending News
More News >

Neuren Pharmaceuticals Issues Unquoted Securities in Employee Share Scheme

Story Highlights
Neuren Pharmaceuticals Issues Unquoted Securities in Employee Share Scheme

Confident Investing Starts Here:

An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.

Neuren Pharmaceuticals Limited announced the issuance of 1,800,000 unquoted securities under an employee share scheme, effective May 23, 2025. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational dynamics and aligning employee interests with shareholder value.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments that address conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in these areas.

Average Trading Volume: 772,549

Technical Sentiment Signal: Hold

Current Market Cap: A$1.63B

For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App